National Pharmacy Health & Leadership Alliance Verify a MemberMember Login
NPHLANational Pharmacy Health & Leadership Alliance
Apply for Membership

02RegulatoryWhat Changed TodayUpdated

What changed today in Regulatory: 1 new study, 1 recall record, 1 safety alert

Every new official record on the Pharmacy, Compounding & Regulatory Intelligence desk since this morning, each linked to its primary source.

By NPHLA IntelligencePublished Last updated Automated from official records

The signal

NPHLA tracked 3 new official records on this desk today: 1 new study, 1 recall record, 1 safety alert.

Why this matters

Federal Register documents and FDA notices can change compliance obligations, deadlines and enforcement priorities for pharmacies, compounders and prescribers.

What changed

  1. New research in Clinical therapeutics: “Glucagon-Like Peptide-1 Receptor Agonist-Associated Hepatotoxicity”.[1]
  2. Recall: G. L. Mezzetta Inc. Announces Recall of Mezzetta Brand Golden Greek Peperoncini (Medium Heat) Due to Presence of Pest Contaminant in the Jar — reason given: not stated (firm: not stated).[2]
  3. Angiographic Catheter Recall: Boston Scientific Removes Imager II Angiographic Catheters[3]
  4. Also reported by American Med Spa Association: “FDA Warning Letter Signals Increased Scrutiny of the Medical Necessity Exception for Compounded GLP-1s”.[4]
  5. Also reported by Drug Topics: “Pharmacy Law Lowdown: FDA’s Evaluation of Peptides”.[5]
  6. Also reported by Healthcare Dive: “Elevance cracks down on hospital billing for off-campus care”.[6]

Who this affects

  • Pharmacies
  • 503A compounders
  • 503B outsourcing facilities
  • Pharmacists
  • Prescribers
  • Practice owners & operators

What to watch next

No new verified deadlines in today’s records. See Deadline Watch for upcoming dates.

NPHLA takeaway

These are factual summaries of official records with no interpretation. Open the primary documents for full details; NPHLA editors add analysis where developments warrant it.

Source file

  1. [1]
  2. [2]
  3. [3]
  4. [4]
    FDA Warning Letter Signals Increased Scrutiny of the Medical Necessity Exception for Compounded GLP-1s

    News reportingAmerican Med Spa AssociationIndustry coverage — headline and link only

  5. [5]
    Pharmacy Law Lowdown: FDA’s Evaluation of Peptides

    News reportingDrug TopicsIndustry coverage — headline and link only

  6. [6]
    Elevance cracks down on hospital billing for off-campus care

    News reportingHealthcare DiveIndustry coverage — headline and link only

Compiled automatically from primary official sources and peer-reviewed literature. Each line is a factual summary of a public record, linked to it — no interpretation is added. NPHLA links to sources and does not republish their text. Professional information only — not medical, legal or regulatory advice for any individual situation. Our standards.

Update timeline

  1. First published.
  2. Added 1 new official record.